BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024

Follow Invezz on Telegram , Twitter , and Google News for instant updates >BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter.BioNTech stock down on muted guidanceCopy link to sectionThe stock is being hit because $BNTX did not issue an impressive guidance either. It now expects revenue to fall between €2.5 billion and €3.1 billion ($2.71 billion to $3.36 billion) this year. Analysts, in comparison, were at €3.44 bi ...